Clean, high‐yield routes are established to the important catalyst chlorobis(tricyclohexylphosphine)ruthenium hydridocarbonyl [RuHCl(CO)(PCy 3 ) 2 ] 2 and its N‐heterocyclic carbene (NHC) derivatives RuHCl(CO)(NHC)(PCy 3 ) ( 3a : NHC=IMes; 3b , NHC=H 2 IMes; IMes=1,3‐dimesitylimidazol‐2‐ylidene). These complexes are obtained by treating chlorotris(tricyclohexylphosphine)ruthenium hydridocarbonyl [RuHCl(CO)(PPh 3 ) 3 ] 1 with tricyclohexylphosphine [PCy 3 ], or with the appropriate NHC ligand, then PCy 3 . Advantages over prior routes to these complexes lie in the high yields from a conveniently accessible precursor, the absence of by‐products that otherwise prove difficult to remove, and the short reaction times under experimentally convenient conditions.
No takes yet. Share an insight, caveat, or question.
Beach et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: